Atea's Hepatitis C Drug Hits Phase 3 Goal, Matching Standard of Care
AVIR sits 75% above its 52-week low of $2.78.
Summary
Atea's Phase 3 C-FORWARD trial met its primary endpoint, with the bemnifosbuvir/ruzasvir combo showing 94% SVR12 versus 95% for the comparator—statistically non-inferior. This is the first efficacy readout from the pivotal program, following Phase 1 data in May and enrollment completion in June. The result de-risks the HCV franchise and supports a potential NDA filing, though the modest premarket move suggests the market had partially priced in success. Detailed data at future medical conferences will be key for assessing competitive positioning against existing DAAs.
At the time of this announcement, AVIR was trading at $4.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.7M. The 52-week trading range was $2.78 to $6.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.